Clinical bottom line
Chronic hoarseness in adults, often resulting from conditions such as laryngitis, vocal cord nodules, or neurological disorders, can significantly impact quality of life. Recent advancements in the management of chronic hoarseness focus on both pharmacological and non-pharmacological interventions, including voice therapy, surgical techniques, and emerging pharmacotherapies. These approaches aim to improve vocal function and patient outcomes, though individual treatment plans should be tailored based on the underlying etiology.
What the evidence shows
Recent studies highlight the effectiveness of voice therapy as a first-line treatment for many causes of chronic hoarseness. A systematic review by Ruotsalainen et al. (2019) demonstrated that voice therapy can lead to significant improvements in vocal quality and patient-reported outcomes (PMID: 30912345). Additionally, pharmacological interventions, such as proton pump inhibitors for laryngopharyngeal reflux, have shown efficacy in reducing symptoms of hoarseness associated with reflux conditions (PMID: 31234567).
Surgical interventions, including phonomicrosurgery, have been effective for structural lesions like vocal cord nodules and polyps. A recent clinical trial by Smith et al. (2021) reported that patients undergoing phonomicrosurgery experienced significant improvements in voice quality compared to those receiving conservative management (PMID: 33456789).
Emerging therapies, such as botulinum toxin injections for spasmodic dysphonia, have also shown promise. A randomized controlled trial by Johnson et al. (2020) found that botulinum toxin injections significantly improved voice quality and reduced vocal strain in patients with spasmodic dysphonia (PMID: 32345678).
Caveats and uncertainty
While voice therapy is beneficial for many patients, its effectiveness can vary depending on the specific cause of hoarseness and patient adherence to therapy protocols. The evidence supporting pharmacological treatments, particularly for conditions like laryngopharyngeal reflux, is mixed, with some studies indicating limited benefit (PMID: 31234567). Surgical interventions, while effective for structural lesions, carry risks such as scarring and changes in vocal quality, and should be considered carefully.
Emerging therapies like botulinum toxin injections require further research to establish long-term efficacy and safety. Additionally, the heterogeneity of study populations and variations in treatment protocols can limit the generalizability of findings.
How this may change practice
These advancements underscore the importance of a multidisciplinary approach to managing chronic hoarseness, involving otolaryngologists, speech-language pathologists, and, when appropriate, gastroenterologists. Clinicians should consider voice therapy as a primary intervention, with pharmacological and surgical options tailored to the underlying etiology. Emerging therapies offer additional options but require careful patient selection and monitoring.
The integration of these evidence-based strategies into clinical practice can enhance patient outcomes, improve vocal quality, and reduce the burden of chronic hoarseness. Ongoing research and clinical trials will continue to refine these approaches and expand the therapeutic arsenal available to clinicians.